Henlius Partners With Mabxience On Trastuzumab
Expands Reach To Argentina, Uruguay and Paraguay
Henlius has struck a deal with Mabxience to market its HLX02 trastuzumab biosimilar in Argentina, Uruguay and Paraguay.
You may also be interested in...
Chinese player Shanghai Henlius Biotech has out licensed semi-exclusive rights to some of its biosimilars in Brazil again, shortly after signing a major deal covering 16 Latin American countries.
Shanghai Henlius Biotech has announced a licensing deal for three biosimilars – bevacizumab, rituximab and trastuzumab – with Brazil’s Eurofarma. The agreement, which could be worth as much as $50.5m, gives the Chinese company enhanced access to Latin America as it continues to broaden its global footprint.
Mabxience has announced plans to bolster its biosimilar manufacturing capacity as well as giving a boost to its CDMO business by expanding its facility in León, Spain.